Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Research & Development (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 9 years of Research & Development data on record, last reported at $10.0 million in Q1 2025.

  • For Q1 2025, Research & Development changed N/A year-over-year to $10.0 million; the TTM value through Mar 2025 reached $29.0 million, changed N/A, while the annual FY2025 figure was $258.8 million, 7.09% up from the prior year.
  • Research & Development reached $10.0 million in Q1 2025 per SNDX's latest filing, down from $15.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $15.0 million in Q3 2024 and bottomed at $2.0 million in Q1 2021.
  • Average Research & Development over 3 years is $7.2 million, with a median of $6.0 million recorded in 2021.
  • The widest YoY moves for Research & Development: up 79.08% in 2021, down 86.12% in 2021.
  • A 3-year view of Research & Development shows it stood at $2.0 million in 2021, then surged by 650.0% to $15.0 million in 2024, then plummeted by 33.33% to $10.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $10.0 million in Q1 2025, $15.0 million in Q3 2024, and $2.0 million in Q3 2021.